Cargando…
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?
At present, there are no proven agents for treatment of coronavirus disease (COVID-19). The available evidence has not allowed guidelines to clearly recommend any drugs outside the context of clinical trials. The novel coronavirus SARS-CoV-2 that causes COVID-19 invokes a hyperinflammatory state dri...
Autores principales: | Atal, Shubham, Fatima, Zeenat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292936/ https://www.ncbi.nlm.nih.gov/pubmed/32535732 http://dx.doi.org/10.1007/s40290-020-00342-z |
Ejemplares similares
-
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
por: Atal, Shubham, et al.
Publicado: (2020) -
Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?
por: Charpiat, Bruno, et al.
Publicado: (2020) -
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19
por: Hum, Christine, et al.
Publicado: (2021) -
Novel Strategies for the Treatment of COVID-19
por: McCarthy, Matthew W.
Publicado: (2022)